Universal Ibogaine Inc (IBO) - Net Assets
Based on the latest financial reports, Universal Ibogaine Inc (IBO) has net assets worth CA$272.17K CAD (≈ $196.89K USD) as of April 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$4.01 Million ≈ $2.90 Million USD) and total liabilities (CA$3.73 Million ≈ $2.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Universal Ibogaine Inc total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$272.17K |
| % of Total Assets | 6.79% |
| Annual Growth Rate | 22.36% |
| 5-Year Change | 944.47% |
| 10-Year Change | N/A |
| Growth Volatility | 24.7 |
Universal Ibogaine Inc - Net Assets Trend (2018–2024)
This chart illustrates how Universal Ibogaine Inc's net assets have evolved over time, based on quarterly financial data. Also explore Universal Ibogaine Inc (IBO) total assets for the complete picture of this company's asset base.
Annual Net Assets for Universal Ibogaine Inc (2018–2024)
The table below shows the annual net assets of Universal Ibogaine Inc from 2018 to 2024. For live valuation and market cap data, see market cap of Universal Ibogaine Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-07-31 | CA$991.11K ≈ $716.95K |
-43.42% |
| 2023-07-31 | CA$1.75 Million ≈ $1.27 Million |
-55.57% |
| 2022-07-31 | CA$3.94 Million ≈ $2.85 Million |
+88566.43% |
| 2021-07-31 | CA$-4.46K ≈ $-3.22K |
-104.70% |
| 2020-07-31 | CA$94.89K ≈ $68.64K |
-51.86% |
| 2019-07-31 | CA$197.12K ≈ $142.59K |
-33.23% |
| 2018-07-31 | CA$295.22K ≈ $213.56K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Universal Ibogaine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2677591500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$28.18 Million | 2842.81% |
| Total Equity | CA$991.11K | 100.00% |
Universal Ibogaine Inc Competitors by Market Cap
The table below lists competitors of Universal Ibogaine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
$1.14 Million |
|
TROUBADOUR RESOURCES INC.
F:2QD0
|
$1.14 Million |
|
NANOSPHERE
F:3NS
|
$1.14 Million |
|
Xplore Resources Corp
V:XPLR
|
$1.14 Million |
|
CT UK High Income Ord
LSE:CHI
|
$1.13 Million |
|
Candela Invest SA
BR:CAND
|
$1.13 Million |
|
DCM Financial Services Limited
NSE:DCMFINSERV
|
$1.13 Million |
|
New Star Investment Trust plc
LSE:NSI
|
$1.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Universal Ibogaine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,751,703 to 991,106, a change of -760,597 (-43.4%).
- Net loss of 2,051,587 reduced equity.
- New share issuances of 1,212,769 increased equity.
- Other factors increased equity by 78,221.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-2.05 Million | -207.0% |
| Share Issuances | CA$1.21 Million | +122.37% |
| Other Changes | CA$78.22K | +7.89% |
| Total Change | CA$- | -43.42% |
Book Value vs Market Value Analysis
This analysis compares Universal Ibogaine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.19x to 1.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-07-31 | CA$0.03 | CA$0.01 | x |
| 2019-07-31 | CA$0.02 | CA$0.01 | x |
| 2020-07-31 | CA$0.01 | CA$0.01 | x |
| 2021-07-31 | CA$0.00 | CA$0.01 | x |
| 2022-07-31 | CA$0.02 | CA$0.01 | x |
| 2023-07-31 | CA$0.01 | CA$0.01 | x |
| 2024-07-31 | CA$0.00 | CA$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Universal Ibogaine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -207.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -88.01%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 4.55x
- Recent ROE (-207.00%) is below the historical average (-131.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -138.30% | 0.00% | 0.00x | 1.09x | CA$-437.81K |
| 2019 | -49.77% | 0.00% | 0.00x | 1.10x | CA$-117.82K |
| 2020 | -124.68% | 0.00% | 0.00x | 1.23x | CA$-127.80K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-290.20K |
| 2022 | -266.20% | -980.22% | 0.17x | 1.60x | CA$-10.89 Million |
| 2023 | -136.46% | -232.08% | 0.19x | 3.14x | CA$-2.57 Million |
| 2024 | -207.00% | -88.01% | 0.52x | 4.55x | CA$-2.15 Million |
Industry Comparison
This section compares Universal Ibogaine Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $26,461,378
- Average return on equity (ROE) among peers: -391.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Universal Ibogaine Inc (IBO) | CA$272.17K | -138.30% | 13.72x | $1.13 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
About Universal Ibogaine Inc
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.